Should IPR Protection for Pharmaceuticals be included in the EU-India FTA?
Rajat Acharyya, Gerrit Faber
Abstract
In its new bilateral trade agreements, the EU tries to include more Intellectual Property Rights (IPR) protection than is provided by the Trade Related Intellectual Property Rights (TRIPS) agreement of the WTO. This has often some far reaching implications. For example, attempts to include IPR protection for pharmaceuticals and drugs in FTA talks with India and Mercosur may threaten the lives of millions of poor all over the world. This note highlights the costs that the world has to bear for such IPR protection. A review of the IPR protection in health care with an open mind is urgently needed to find an answer to why it has not delivered the good for most of the poor in the world.
Full Text: PDF